Now, a safety activist who's former head of the National Highway Traffic Safety Administration is asking for a probe of NHTSA, which she said "failed to carry out the law" when it didn't force GM to fix the problem back then.
GM recalled 1.37 million cars in the U.S. last month because faulty ignition switches can shut off power to the front airbags. GM says it knows of 31 crashes and 13 deaths linked to the fault.
Former NHTSA Administrator Joan Claybrook, a long-time safety activist and frequent critic of General Motors, says in a letter to the federal safety agency that "NHTSA has responsibility for failing to order a recall by early 2007, when it knew what the defect was and how to fix it."
Top 5 Gas Utility Companies To Buy For 2016: Biota Pharmaceuticals Inc (BOTA)
Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.
The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.
Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.
PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.
Advisors' Opinion:- [By gurujx]
Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42
The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.
Top Industrial Disributor Stocks To Own Right Now: The KEYW Holding Corporation(KEYW)
The KEYW Holding Corporation, through its subsidiaries, provides mission-critical cybersecurity and cyber superiority solutions to defense, intelligence, and national security agencies in the United States. Its solutions, services, and products support the collection, processing, analysis, and use of intelligence data and information in the domain of cyberspace. The company offers engineering services and solutions to solve discreet and complex cybersecurity, cyber superiority, and intelligence challenges; and specialized training, field support, and test and evaluation services. The KEYW Holding Corporation is also involved in collecting data and information in cyberspace encompassing the entire electromagnetic spectrum; processing data and information from cyberspace to make it accessible to a range of analytical needs and resources; analyzing data and information that is collected, processed, correlated, and made accessible to transform them into usable information for its customers. In addition, it impacts or creates integrated intelligence data and information, which is used in observing, preventing, and responding to known and emerging threat events, actions, and agents in a real time. Further, the company engages in the development, integration, deployment, and sustainment of agile airborne intelligence, surveillance, and reconnaissance collection platforms to austere environments. Additionally, it develops and sells hardware products to create intelligence insight and capture information that help identify, locate, and monitor activity to its intelligence agency customers. The KEYW Holding Corporation is headquartered in Hanover, Maryland.
Advisors' Opinion:- [By Roberto Pedone]
KEYW Holding (KEYW), through its subsidiaries, provides mission-critical cybersecurity, cyber superiority, and geospatial intelligence solutions to the U.S. Government defense, intelligence, and national security agencies, and commercial enterprises. This stock closed up 5.5% to $10.70 in Monday's trading session.
Monday's Volume: 1.27 million
Three-Month Average Volume: 601,773
Volume % Change: 108%From a technical perspective, KEYW ripped higher here right off its recent low of $9.98 with above-average volume. This stock has been downtrending badly for the last two months and change, with shares sliding lower from its high of $23.09 to its recent 52-week low of $9.98. During that downtrend, shares of KEYW have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of KEYW are now starting to rebound off its 52-week low of $9.98 with strong upside volume flows. This move could be signaling a trend change is in the cards for KEYW in the short-term.
Traders should now look for long-biased trades in KEYW as long as it's trending above Monday's low of $10.31 or above its 52-week low of $9.98 and then once it sustains a move or close above Monday's high of $11.15 to some more near-term overhead resistance at $11.50 with volume that hits near or above 601,773 shares. If that move kicks off soon, then KEYW will set up to re-test or possibly take out its next major overhead resistance levels at $13.35 to its 200-day moving average of $14.37.
- [By Seth Jayson]
KEYW Holding (Nasdaq: KEYW ) reported earnings on April 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), KEYW Holding beat expectations on revenues and missed expectations on earnings per share. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on KEYW Holding (Nasdaq: KEYW ) , whose recent revenue and earnings are plotted below.
Top Industrial Disributor Stocks To Own Right Now: ING Prime Rate Trust (PPR)
ING Prime Rate Trust (the Trust) is a diversified closed-end management investment company. The Trust seeks to provide a high a level of current income together with the preservation of capital. It invests least 80% of its net assets, plus the amount of any borrowings for investment purposes, in United States dollar-denominated, floating-rate secured senior loans. It also invests a substantial portion of its assets in below investment-grade senior loans and other below investment-grade assets.
The Trust invests in sectors, such as healthcare, education and childcare; cable; chemicals, plastics and rubber; utilities; printing and publishing; leisure, amusement and entertainment; oil and gas; retail stores; data and Internet services, and beverage, food and tobacco. The Trust�� investment advisor is ING Investments, LLC. ING Prime Rate Trust�� sub-advisor is ING Investment Management Co. and its administrator is ING Funds Services, LLC. ING Investments, LLC, ING Investment Management Co. and ING Funds Services, LLC are indirect, wholly owned subsidiaries of ING Groep N.V.
Advisors' Opinion:- [By John Dowdee]
The following 10 funds satisfied all of these conditions:
BlackRock Float Rate Strategies (FRA). This CEF sells at a discount of 3%, which is low compared to an average premium of 2% over the past year. The distribution has been managed at 6.1% and a small amount (less than 10%) has been return of capital (ROC). However, this has not negatively affected net asset value (NAV) so has not been destructive. The fund holds 447 securities, with 90% in floating rate loans. FRA utilizes 27% leverage and has an expense ratio of 1.7%, including interest payments. Eaton Vance Floating Rate (EFR). This CEF sells at a 1% premium, which is low compared to an average premium of 5% over the past year. The distribution is 6.2%, none of which was ROC. The fund holds 800 securities, with 90% in floating rate loans. About 85% of the securities are from U.S. companies. EFR utilizes 35% leverage and has an expense ratio of 1.8% including interest payments. ING Prime Rate Trust (PPR). This CEF sells for a premium of 2%, which is below the average premium of 5%. It has a distribution of 6.8%, none of which was ROC. The fund has 350 holdings, virtually all in senior loans and from US companies. PPR utilizes 29% leverage and has a high expense ratio of 2.1%, including interest payments. Invesco VK Dynamic Credit Opportunities (VTA). This CEF sells for a discount of 5%, which is below the average discount of 1%. It has a distribution of 7.1%, none of which was ROC. The fund has 495 holdings, with 76% in floating rate loans. About 25% of the loans are from non-US companies. VTA utilizes a relatively low 20% leverage but still has a high expense ratio of 2.1%, including interest payments. Invesco VK Senior Income (VVR). This CEF sells for a discount of 1%, which is below the average premium of 3%. It has a distribution of 7.1%, none of which was ROC. The fund has over 500 holdings, with 89% in floating rate loans. Almost all (95%) securities are from US companies. VVR ut - [By Aaron Levitt]
The main reason why investors fled bounds during the taper tantrum is that bond prices have a negative correlation with rising interest rates. The ING Prime Rate Trust (PPR) avoids some of those problems.
Top Industrial Disributor Stocks To Own Right Now: Seattle Genetics Inc.(SGEN)
Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Advisors' Opinion:- [By Sean Williams]
These might not be household names in the U.S., but they do brandish global licensing partnerships with companies that might be more familiar to you. Takeda, for example, has licensing agreements in place with Orexigen Therapeutics (NASDAQ: OREX ) , which recently filed a New Drug Application for its chronic weight management (i.e., anti-obesity) pill, Contrave, in the U.S. Takeda owns the right to Contrave outside of North America. In addition, Takeda is a collaborative partner of antibody-drug conjugate developer Seattle Genetics (NASDAQ: SGEN ) with regard to FDA-approved Hodgkin lymphoma drug Adcetris.�
- [By Rich Bieglmeier]
[Related -Seattle Genetics, Inc. (SGEN), Takeda Report Encouraging Data From ADCETRIS Study]
Let's take a look at what $2 billion in ADCETRIS sales could mean for the stock price and where SGEN shares would need to trade to become a low-end large cap stock.
- [By Lee Jackson]
While very upbeat on the sector as a whole, UBS was very cautious on sell-rated Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD) and ImmunoGen Inc. (NASDAQ: IMGN). Neutral-rated Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Seattle Genetics Inc. (NASDAQ: SGEN) were also viewed with a skeptical eye.
- [By Motley Fool Staff]
Whether it's in the abstract or at the meeting, I'm looking forward to seeing Seattle Genetics' (NASDAQ: SGEN ) data from its Aethera trial, testing Adcetris immediately following an autologous stem cell transplantation in patients with Hodgkin lymphoma. The biotech already reported a 75% improvement in progression-free survival -- living without the disease progressing -- but the details of how the patients are responding are more important than the top-line data.
Top Industrial Disributor Stocks To Own Right Now: Shionogi & Co Ltd (SGIOF.PK)
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company. It is engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides vitamin preparations, analgesic antipyretics, eye care products, cold and sinus medicine, digestive medicine, dermatologic preparations, antiphlogistic analgetics, antihypercholesterolemic agents, test paper for glucose in urine and artificial teeth-related products. As of March 31, 2013, the Company had 32 consolidated subsidiaries and six associated companies. Advisors' Opinion:- [By Jason Melehani]
ViiV Healthcare, a collaborative HIV focused venture established by GlaxoSmithKline (GSK), Pfizer (PFE) and Shionogi & Co (SGIOF.PK), is seeking approval from the FDA and the European Union for dolutegravir, an integrase inhibitor used for the treatment of HIV. Integrase inhibitors act by preventing the reverse transcribed viral DNA from integrating into the human T cell DNA.
No comments:
Post a Comment